Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Want to stay up-to-date on the very latest developments in non-malignant haematology? Don't have the time or skills to critically appraise important papers? Join Pip and Rich, two haematology doctors on a journey of learning and discovery. Each episode, they will discuss a seminal trial, critically appraise the paper, interview a study author, and discuss the implications of the trial on clinical practice with a subject expert. CPD credits are available from RCPath. The podcast is sponsored by Sobi as a hands-off educational grant. Sobi have no editorial input whatsoever.
This podcast helps you to go beyond the abstract, delving deep into the methods, results, subanalyses, and implications. Interviews with authors gives a real-life perspective on the running of a clinical trial allowing explanations of why they did what they did and good honest discussion on limitations and how they might do it differently next time.
Hosted on Acast. See acast.com/privacy for more information.
| Episode | Date |
|---|---|
|
Using AI to identify hospital acquired thrombosis
|
May 26, 2026 |
|
Apixaban vs rivaroxaban: the trial we've all been waiting for
|
Mar 17, 2026 |
|
ENERGIZE: Mitapivat in thalassaemia
|
Feb 27, 2026 |
|
Ianalumab for ITP: VAYHIT2
|
Feb 10, 2026 |
|
Highlights of 2025 (Episode 2)
|
Jan 09, 2026 |
|
Highlights of 2025 (Episode 1)
|
Dec 26, 2025 |
|
Does anyone care about idiopathic and secondary polycythaemia? We do!
|
Dec 09, 2025 |
|
Rebalancing haemostasis with marstacimab - an discussion about the BASIS trial
|
Nov 13, 2025 |
|
BSH President Dr Sue Pavord: An Interview
|
Oct 29, 2025 |
|
DJRTA Newsletter #2
|
Oct 22, 2025 |
|
Intervention for Intermediate-High Risk PE
|
Oct 15, 2025 |
|
Introducing the DJRTA Newsletter
|
Oct 07, 2025 |
|
HI-PRO: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
|
Sep 30, 2025 |
|
API-CAT: Author interview with Prof. Isabelle Mahé
|
Sep 15, 2025 |
|
API-CAT: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
|
Jul 21, 2025 |
|
LUNA3: Rilzabrutinib for ITP
|
Jul 06, 2025 |
|
Haematology in The Gambia with Dr Megan Kell
|
Jun 12, 2025 |
|
Efanesoctocog alfa for severe haemophilia A: expert perspective with Dr Susie Shapiro
|
May 30, 2025 |
|
Efanesoctocog alfa - a very long half life factor VIII
|
May 16, 2025 |
|
BSH Day 2
|
Apr 28, 2025 |
|
BSH Day 1
|
Apr 27, 2025 |
|
Preview of BSH 2025: a focus on medical haematology
|
Apr 18, 2025 |
|
PEERLESS - Management of Acute Intermediate-Risk PE
|
Apr 04, 2025 |
|
AI powered ultrasound for DVT - an interview with CEO of ThinkSono, Fouad Al Noor
|
Mar 21, 2025 |
|
Iptacopan for PNH
|
Mar 07, 2025 |
|
Plasma exchange free treatment of TTP: Author Discussion
|
Feb 21, 2025 |
|
Plasma exchange free treatment of TTP
|
Jan 31, 2025 |
|
Exa-cel for severe sickle cell disease
|
Nov 12, 2024 |
|
ANNEXA-I: Discussion with Dr Will Lester
|
Oct 02, 2024 |
|
ANNEXA-I
|
Aug 22, 2024 |
|
VITT, HIT, and spontaneous syndromes
|
May 26, 2024 |
|
Efgartigimod for ITP
|
Apr 16, 2024 |
|
FRAIL-AF
|
Mar 04, 2024 |
|
The PACER trial
|
Jan 21, 2024 |